Fibroadenoma Market Research Report Information by Type (Simple Fibroadenoma and Complex Fibroadenoma), by Diagnosis & Treatment (Diagnosis [Ultrasound Scan, Mammography, and Biopsy] and Treatment [Cryoablation, High Intensity Focused Ultrasound (HIFU), Lumpectomy, and Drugs {Dydrogesterone, Medroxyprogesterone, Selective Estrogen Receptor Modulators, and Others}], by End User (Hospital and Clinics, Diagnostic Centers, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) – Forecast till 2032
Market Dynamics
In 2023, the fibroadenoma market is expected to be USD 0.71 billion. Exhibiting a compound annual growth rate (CAGR) of 6.36%, the Fibroadenoma Market industry is expected to rise from USD 0.77 billion in 2024 to USD 1.34 billion by 2032.
The main forces driving the expansion of the fibroedema market are public education initiatives raising awareness of fibroadenoma and growing prevalence of fibroadenoma among women.
One clear main driver in the fibroadenoma market is growing public knowledge of fibroadenoma resulting from public education programs. Public education initiatives are quite important in guiding women on the indicators and symptoms of fibroadenoma. This increased consciousness motivates women to get regular breast exams and screenings as well as to engage in proactive health-seeking activity. Timeliness of action and suitable therapy of fibroadenomas depend on early discovery. Public education initiatives also serve to debunk false ideas and misunderstandings about breast lumps, therefore reducing unwarranted tension and concern related with such results.
Moreover, the expansion of the fibroadenoma market is clearly driven by the development of better diagnostic tools. Timely and suitable medical action depends on accurate identification of fibroadenomas, thus developments in diagnostic instruments have greatly improved the detection accuracy. Improved diagnostic methods let doctors find fibroadenomas earlier on. Implementing prompt and focused treatment plans, lowering the possibility for complications, and enhancing patient outcomes all depend on early diagnosis of this kind. The diagnosis approach to fibroadenomas has been transformed by the advent and improvement of non-invasive imaging technologies including magnetic resonance imaging (MRI) and ultrasonic waves.
Insights of Market Segments
Type dictates that the Fibroadenoma Market consists of simple and complex fibroadenoma.
The fibroadenoma market is split based on diagnosis and treatment.
The fibroadenoma market is divided depending on end user into others, ambulatory surgical centers, and hospitals and clinics.
Regional Analysis
Thanks to the sophisticated diagnostic technologies and medical infrastructure as well as reimbursement policies and insurance coverage, North America accounted for the biggest market share of about 38.49% in 2022. Moreover, compared to other areas, North Americans have easier access to healthcare and show more awareness of health problems. Consequently, even in asymptomatic instances, more frequent visits and fibroadenoma diagnosis follow from this.
Because minimally invasive treatments for fibroadenomas including cryoablation and vacuum-assisted excision—particularly strong in Europe—show great growth in the Europe fibroadenoma market over the projected year, i.e., 2024–2032. The local hospitals and clinics draw people looking for less intrusive choices since they are ready to execute these operations.
The fastest-growing area throughout the projection period is the Asia-Pacific fibroadenoma market since regular expansion of breast diagnosis and treatment equipment drives frequent launch of machines. IceCure Medical LTD. declared in May 2023 that ProSense was installed and opened at Kovai Medical Center and Hospital ("KMCH") in India.
Main Players
Important companies in the Fibroadenoma Market are GE Healthcare (US), Koninklijke Philips N.V. (Germany), Shimadzu Corporation (Japan), Siemens Healthineers (Germany), Canon Medical Systems Corporation (Japan), Dilon Technologies (US), Pfizer, Inc. (US), IceCure Medical (Israel), Alpinion Medical Systems (South Korea), and Fujifilm Holdings Corporation (Japan).
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 3 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY SIMPLE FIBROADENOMA, 2019-2032 (USD MLLION)
TABLE 4 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY COMPLEX FIBROADENOMA, 2019-2032 (USD MLLION)
TABLE 5 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 6 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY DIAGNOSIS, 2019-2032 (USD MLLION)
TABLE 7 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY TREATMENT, 2019-2032 (USD MLLION)
TABLE 8 GLOBAL FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 9 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY HOSPITAL AND CLINICS, 2019-2032 (USD MLLION)
TABLE 10 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY DIAGNOSTIC CENTERS, 2019-2032 (USD MLLION)
TABLE 11 GLOBAL FIBROADENOMA MARKET ESTIMATES & FORECAST, BY OTHERS, 2019-2032 (USD MLLION)
TABLE 12 GLOBAL FIBROADENOMA MARKET, BY REGION, 2019-2032 (USD MLLION)
TABLE 13 NORTH AMERICA FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)
TABLE 14 NORTH AMERICA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 15 NORTH AMERICA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 16 NORTH AMERICA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 17 US FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 18 US FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 19 US FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 20 CANADA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 21 CANADA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 22 CANADA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 23 MEXICO FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 24 MEXICO FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 25 MEXICO FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 26 EUROPE FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)
TABLE 27 EUROPE FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 28 EUROPE FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 29 EUROPE FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 30 GERMANY FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 31 GERMANY FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 32 GERMANY FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 33 FRANCE FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 34 FRANCE FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 35 FRANCE FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 36 UK FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 37 UK FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 38 UK FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 39 SPAIN FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 40 SPAIN FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 41 SPAIN FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 42 ITALY FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 43 ITALY FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 44 ITALY FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 45 REST OF EUROPE FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 46 REST OF EUROPE FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 47 REST OF EUROPE FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 48 ASIA PACIFIC FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)
TABLE 49 ASIA PACIFIC FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 50 ASIA PACIFIC FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 51 ASIA PACIFIC FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 52 CHINA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 53 CHINA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 54 CHINA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 55 INDIA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 56 INDIA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 57 INDIA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 58 JAPAN FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 59 JAPAN FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 60 JAPAN FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 61 SOUTH KOREA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 62 SOUTH KOREA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 63 SOUTH KOREA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 64 AUSTRALIA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 65 AUSTRALIA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 66 AUSTRALIA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 67 REST OF ASIA PACIFIC FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 68 REST OF ASIA PACIFIC FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 69 REST OF ASIA PACIFIC FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 70 REST OF THE WORLD FIBROADENOMA MARKET, BY COUNTRY, 2019-2032 (USD MLLION)
TABLE 71 REST OF THE WORLD FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 72 REST OF THE WORLD FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 73 REST OF THE WORLD FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 74 SOUTH AMERICA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 75 SOUTH AMERICA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 76 SOUTH AMERICA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 77 MIDDLE EAST & AFRICA FIBROADENOMA MARKET, BY TYPE, 2019-2032 (USD MLLION)
TABLE 78 MIDDLE EAST & AFRICA FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MLLION)
TABLE 79 MIDDLE EAST & AFRICA FIBROADENOMA MARKET, BY END-USER, 2019-2032 (USD MLLION)
TABLE 80 PUBLIC PLAYERS STOCK SUMMARY
TABLE 81 PRODUCT LAUNCH
TABLE 82 PARTNERSHIP
TABLE 83 EXPANSION
TABLE 84 GE HEALTHCARE: PRODUCTS OFFERED
TABLE 85 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
TABLE 86 SHIMADZU CORPORATION: PRODUCTS OFFERED
TABLE 87 SHIMADZU CORPORATION: KEY DEVELOPMENTS
TABLE 88 SIEMENS HEALTHINEERS: PRODUCTS OFFERED
TABLE 89 SIEMENS HEALTHINEERS: KEY DEVELOPMENTS
TABLE 90 CANON MEDICAL SYSTEMS CORPORATION: PRODUCTS OFFERED
TABLE 91 CANON MEDICAL SYSTEMS CORPORATION: KEY DEVELOPMENTS
TABLE 92 DILON TECHNOLOGIES: PRODUCTS OFFERED
TABLE 93 DILON TECHNOLOGIES: KEY DEVELOPMENTS
TABLE 94 PFIZER, INC: PRODUCTS OFFERED
TABLE 95 ICECURE MEDICAL: PRODUCTS OFFERED
TABLE 96 ALPINION MEDICAL SYSTEMS: PRODUCTS OFFERED
TABLE 97 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED
LIST OF FIGURES
FIGURE 1 GLOBAL FIBROADENOMA MARKET: STRUCTURE
FIGURE 2 GLOBAL FIBROADENOMA MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2032)
FIGURE 4 PORTER’S FIVE FORCES MODEL: GLOBAL FIBROADENOMA MARKET
FIGURE 5 GLOBAL FIBROADENOMA MARKET, BY TYPE, SEGMENT ATTRACTIVENESS ANALYSIS
FIGURE 6 GLOBAL FIBROADENOMA MARKET, BY TYPE, 2022 (% SHARE)
FIGURE 7 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, SEGMENT ATTRACTIVENESS ANALYSIS
FIGURE 8 GLOBAL FIBROADENOMA MARKET, BY DIAGNOSIS & TREATMENT, 2022 (% SHARE)
FIGURE 9 GLOBAL FIBROADENOMA MARKET, BY END-USER, SEGMENT ATTRACTIVENESS ANALYSIS
FIGURE 10 GLOBAL FIBROADENOMA MARKET, BY END-USER, 2022 (% SHARE)
FIGURE 11 GLOBAL FIBROADENOMA MARKET, BY REGION, 2022 (% SHARE)
FIGURE 12 NORTH AMERICA MARKET: COMPARATIVE ANALYSIS
FIGURE 13 NORTH AMERICA MARKET: SWOT ANALYSIS
FIGURE 14 NORTH AMERICA FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)
FIGURE 15 EUROPE MARKET: COMPARATIVE ANALYSIS
FIGURE 16 EUROPE FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)
FIGURE 17 EUROPE MARKET: SWOT ANALYSIS
FIGURE 18 ASIA PACIFIC MARKET: COMPARATIVE ANALYSIS
FIGURE 19 ASIA PACIFIC FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)
FIGURE 20 ASIA PACIFIC MARKET: SWOT ANALYSIS
FIGURE 21 REST OF THE WORLD MARKET: COMPARATIVE ANALYSIS
FIGURE 22 REST OF THE WORLD FIBROADENOMA MARKET, BY COUNTRY, 2022 (% SHARE)
FIGURE 23 REST OF THE WORLD MARKET: SWOT ANALYSIS
FIGURE 24 COMPETITOR DASHBOARD: GLOBAL FIBROADENOMA MARKET
FIGURE 25 GLOBAL FIBROADENOMA MARKET: COMPETITIVE ANALYSIS, 2022
FIGURE 26 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 GE HEALTHCARE: SWOT ANALYSIS
FIGURE 28 KONINKLIJKE PHILIPS N.V.: SWOT ANALYSIS
FIGURE 29 SHIMADZU CORPORATION: SWOT ANALYSIS
FIGURE 30 SIEMENS HEALTHINEERS: SWOT ANALYSIS
FIGURE 31 CANON MEDICAL SYSTEMS CORPORATION: SWOT ANALYSIS
FIGURE 32 DILON TECHNOLOGIES: SWOT ANALYSIS
FIGURE 33 PFIZER, INC: SWOT ANALYSIS
FIGURE 34 ICECURE MEDICAL: SWOT ANALYSIS
FIGURE 35 ALPINION MEDICAL SYSTEMS: SWOT ANALYSIS
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們